![A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies | British Journal of Cancer A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2016.59/MediaObjects/41416_2016_Article_BFbjc201659_Fig1_HTML.jpg)
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies | British Journal of Cancer
![A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus - Diabetes A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus - Diabetes](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fa38745c-22be-4ef4-ae18-940493514ad4/gr1_lrg.jpg)
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus - Diabetes
![Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial) | BMC Pediatrics | Full Text Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial) | BMC Pediatrics | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12887-021-02975-8/MediaObjects/12887_2021_2975_Fig1_HTML.png)
Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial) | BMC Pediatrics | Full Text
![Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8e81730c-8535-4910-96ce-cc5c3da526ac/gr2_lrg.jpg)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer
![Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials - Annals of Oncology Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3ca2ce18-2988-439f-9244-3773736cb7af/gr1_lrg.jpg)
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials - Annals of Oncology
![A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study - The Lancet Microbe A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study - The Lancet Microbe](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/81a6f7ea-13f1-4051-b316-e041ce5b17d6/gr1.gif)
A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study - The Lancet Microbe
![Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41573-019-0034-3/MediaObjects/41573_2019_34_Fig1_HTML.png)
Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery
![Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials - ScienceDirect Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2451865417301734-gr1.jpg)
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials - ScienceDirect
![Frontiers | Exploration of the Optimal Desmopressin Treatment in Children With Monosymptomatic Nocturnal Enuresis: Evidence From a Chinese Cohort | Pediatrics Frontiers | Exploration of the Optimal Desmopressin Treatment in Children With Monosymptomatic Nocturnal Enuresis: Evidence From a Chinese Cohort | Pediatrics](https://www.frontiersin.org/files/Articles/626083/fped-08-626083-HTML/image_m/fped-08-626083-g001.jpg)
Frontiers | Exploration of the Optimal Desmopressin Treatment in Children With Monosymptomatic Nocturnal Enuresis: Evidence From a Chinese Cohort | Pediatrics
![Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose- finding, phase 1/2a study - The Lancet Infectious Diseases Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose- finding, phase 1/2a study - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2048237137/2058284958/gr1.gif)
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose- finding, phase 1/2a study - The Lancet Infectious Diseases
![Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs | BMC Medicine | Full Text Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12916-020-01808-2/MediaObjects/12916_2020_1808_Fig3_HTML.png)
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs | BMC Medicine | Full Text
![Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) - Musuamba - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) - Musuamba - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/963715fb-15d1-40b7-982d-d2e42d8fafac/psp412196-fig-0002-m.jpg)
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) - Musuamba - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
![Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis - Gastroenterology Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/59579949-6e42-4222-a9da-6bd65533780f/gr1_lrg.jpg)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis - Gastroenterology
![Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy - ScienceDirect Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1551714420301610-gr1.jpg)
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy - ScienceDirect
How to design a dose-finding study on combined agents: Choice of design and development of R functions
![Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/01ae8c0c-dfd8-4d41-ac84-4e4ef2c44353/gr1.jpg)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer - European Journal of Cancer
![Study design. (A) The dose-escalation design included two main steps... | Download Scientific Diagram Study design. (A) The dose-escalation design included two main steps... | Download Scientific Diagram](https://www.researchgate.net/profile/Lucia-Vigano/publication/38077856/figure/fig1/AS:315172368470016@1452154356606/Study-design-A-The-dose-escalation-design-included-two-main-steps-with-ridaforolimus.png)
Study design. (A) The dose-escalation design included two main steps... | Download Scientific Diagram
![Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop | SpringerLink Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00134-020-05934-6/MediaObjects/134_2020_5934_Fig1_HTML.png)